AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Zacks.com featured highlights include AMN Healthcare Services, Hawkins and Arthur J. Gallagher
by Zacks Equity Research
AMN Healthcare Services, Hawkins and Arthur J. Gallagher have been highlighted in this Screen of the Week article.
Neogen's (NEOG) Q3 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Robust segmental performance and contributions from the Soleris product line drive the top line for Neogen (NEOG) in third-quarter of fiscal 2022 results.
Reasons to Retain Intuitive Surgical (ISRG) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.
3 Top Stocks to Invest In for Solid Earnings Growth
by Tirthankar Chakraborty
Invest in stocks like AMN Healthcare Services (AMN), Hawkins (HWKN) & Arthur J. Gallagher (AJG) at the moment for super earnings growth.
AMN Healthcare Services (AMN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AMN Healthcare Services (AMN) closed at $103.47, marking a -1% move from the previous day.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and strategic deals.
Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher (TMO) on its progress with COVID-19-related products and services.
QIAGEN (QGEN) QuantiFeron Hits New Sales Landmark in TB Testing
by Zacks Equity Research
According to QIAGEN (QGEN), QuantiFERON is different from other IGRA tests based on its efficient workflow.
HealthEquity (HQY) Q4 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, along with recording robust Custodial and Interchange revenues, in the fourth quarter of fiscal 2022.
Here's Why You Should Invest in Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in the Animal Health business and dental business.
Philips (PHG) Ties Up With Nuvo Group to Boost Maternal Care
by Zacks Equity Research
Philips (PHG) collaborates with Nuvo to develop maternity care services with digital solutions and eco-system building in rural areas
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.
Fresenius Medical's (FMS) Merger Deal to Improve Kidney Care
by Zacks Equity Research
Fresenius Medical's (FMS) merger deal to build an independent entity to transform kidney care and health equity throughout the United States.
Henry Schein (HSIC) Stock Moves Up 16.9%: What's Driving It?
by Zacks Equity Research
Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.
Syneos Health (SYNH) Clinical Solutions Arm Grows Amid Cost Woe
by Zacks Equity Research
Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.
Thermo Fisher's (TMO) New Buyouts Aid, Cost Pressure Ails
by Zacks Equity Research
Thermo Fisher's (TMO) high degree of response to the pandemic has enabled it to accelerate its growth strategy, strengthen customer relationships, and bump up investments.
Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
Here's Why You Should Retain ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment toward clinical studies. However, limited commercial expertise is a woe.
Myriad Genetics (MYGN) Makes Progress in Precision Oncology
by Zacks Equity Research
Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.
Reasons to Add Allscripts (MDRX) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts Healthcare Solutions (MDRX) owing to its strategic alliances.
Catalent's (CTLT) New Project Completion Expands Global Footprint
by Zacks Equity Research
Catalent's (CTLT) latest facility transformation is likely to significantly enhance the global Biologics business.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain traction from its robust strategic deals. However, stiff competition remains a woe.
Cardinal Health (CAH) Unveils the First Surgical Incise Drape
by Zacks Equity Research
Cardinal Health's (CAH) introduction of the first surgical incise drape is likely to lower SSIs.
AMN vs. GDRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.